Liver injury is a potential complication of many different
|
|
- Debra Matthews
- 5 years ago
- Views:
Transcription
1 LIVER INJURY/REGENERATION Oral Medications with Significant Hepatic Metabolism at Higher Risk for Hepatic Adverse Events Craig Lammert, 1 Einar Bjornsson, 2 Anna Niklasson, 2 and Naga Chalasani 3,4 Reactive metabolites generated by hepatic metabolism are thought to play an important role in the pathogenesis of drug-induced liver injury (DILI), but supporting data are limited. If this is true, then compounds with significant hepatic metabolism should cause more DILI than those without it. We conducted a study to examine the relationship between hepatic metabolism and DILI of prescription medications. We systematically extracted the metabolism characteristics of 207 of the most widely prescribed oral medications in the United States. Compounds with >50% hepatic metabolism were characterized as those with significant hepatic metabolism (n 149). Hepatic adverse events of interest were alanine aminotransferase >3 times the upper limit of normal, jaundice, liver failure, liver transplantation, or fatal DILI. Compared with compounds with lesser hepatic metabolism, compounds belonging to the significant hepatic metabolism group had significantly higher frequency of alanine aminotransferase >3 times the upper limit of normal (35% versus 11%, P 0.001), liver failure (28% versus 9%, P 0.004), and fatal DILI (23% versus 4%, P 0.001), but not jaundice (46% versus 35%, P 0.2) or liver transplantation (9% versus 2%, P 0.11). Twelve compounds with no hepatic metabolism had no reports of liver failure, liver transplantation, or fatal DILI. When the relationship between hepatic adverse events and combination of hepatic metabolism and daily dose was examined, compounds with both significant hepatic metabolism and daily dose >50 mg (n 50) were significantly more hepatotoxic than compounds belonging to other groups. Compared with medications without biliary excretion, compounds with biliary excretion (n 50) had significantly higher frequency of jaundice (74% versus 40%, P ). Conclusion: Our study finds an important relationship between a compound s metabolism profile and reports of hepatic adverse events. (HEPATOLOGY 2010;51: ) Liver injury is a potential complication of many different drugs. This is not surprising, given the important role played by the liver in the metabolism and excretion of drugs from the body. Most drugs undergo some metabolism in the liver before excretion by Abbreviations: ALT, alanine aminotransferase; CYP, cytochrome P450 enzyme; DILI, drug-induced liver injury; ULN, upper limit of normal. From the 1 Department of Medicine, Emory University School of Medicine, Atlanta, GA; the 2 Division of Gastroenterology and Hepatology, Sahlgrenska University Hospital, Gothenburg, Sweden; the 3 Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN; and the 4 Clarian/ Indiana University Digestive Disease Diseases Center, Indianapolis, IN. Received February 27, 2009; accepted September 3, Supported by Public Health Service Grant K24DK (to N. C.). Address reprint requests to: Naga Chalasani, M.D., F.A.C.G., Professor of Medicine, Director, Division of Gastroenterology and Hepatology, Indiana University School of Medicine, 1050 Wishard Boulevard, RG 4100, Indianapolis, IN nchalasa@iupui.edu; fax: Copyright 2009 by the American Association for the Study of Liver Diseases. Published online in Wiley InterScience ( DOI /hep Potential conflict of interest: Nothing to report. Additional Supporting Information may be found in the online version of this article. the kidneys or through bile, though some drugs have little or no metabolism within the liver. Two major biotransformation phases have been identified for drugs metabolized in the liver. 1 The hepatic metabolism of xenobiotics involves either phase I followed by phase II reactions or phase I reactions alone or rarely only phase II reactions. 1 Phase I reactions are catalyzed by the cytochrome P450 enzymes (CYPs) potentially leading to formation of reactive metabolites. 1 The reactive drug metabolites generated through phase I reactions can potentially lead to liver injury, but phase II reactions are important in detoxifying these reactive metabolites. These reactive metabolites or intermediates are in many instances metabolized further by phase II reactions that involve their conjugation with endogenous molecules such as glutathione, glucuronate, sulfate, or acetate in order to make them more water soluble and more easily eliminated from the body. 1 Formation of toxic reactive metabolites has been suggested as potential mechanism for causing idiosyncratic drug-induced liver injury (DILI). 2-5 Hepatic CYPs that generate reactive intermediates are largely concentrated in 615
2 616 LAMMERT ET AL. HEPATOLOGY, February 2010 the centrilobular zone (zone III), an area that is predominantly affected in some forms of DILI (e.g., acetaminophen or halothane toxicity). 6 These reactive metabolites may potentially bind to various cellular proteins and subsequently make them targets for immunomediated cell injury. 5,7 However, the role of phase II reactions in causing DILI cannot be excluded. A rodent model suggested that diclofenac-adducts generated by glucuronidation may play an important role in the pathogenesis of diclofenac-induced liver injury, although evidence directly implicating its acyl-glucuronide derivative is lacking. 8 Many experts believe that reactive metabolites play an important role in the pathogenesis of DILI. 2-5 If this theory was true, then compounds that are metabolized by the liver should have higher frequency of DILI than compounds without hepatic metabolism. However, some drugs without significant hepatic metabolism may cause serious DILI (e.g., ximelagatran). 9,10 We conducted a study to test the hypothesis that compounds with significant hepatic metabolism cause DILI at a greater frequency than compounds with lesser degrees of hepatic metabolism. Using two comprehensive pharmaceutical databases, we examined the relationship between hepatic metabolism of commonly prescribed medications and their reported ability to cause hepatotoxicity. Materials and Methods A widely available pharmaceutical database (www. drugtopics.com) was used to generate the names of the top 200 brand and top 200 generic medications by prescription volume in the United States for the year ,12 Only oral medications were included, and compounds listed in both the brand and generic lists were considered one entry. Entries with more than one active compound (i.e., fixed drug formulations) and those containing acetaminophen compounds were excluded. These criteria identified 207 individual compounds that were considered eligible for inclusion in this study. These compounds were subsequently categorized into those with and without significant hepatic metabolism based on information contained within Thompson s Micromedex DRUGDEX System, 13 PubMed, Therapeutic Drugs by Dollery, 14 the AHFS Drug Information textbook, 15 and FASS (the Swedish Information Medicines Engine). 16 The compounds with 50% hepatic metabolism were categorized into a significant hepatic metabolism group, whereas compounds with 50% hepatic metabolism were categorized into a nonsignificant hepatic metabolism group (for example: allopurinol, with approximately 80% of the compound metabolized in the liver, was placed in the significant hepatic metabolism group). A 50% cutoff was chosen a priori arbitrarily based on consensus of the authors. For compounds that are pro-drugs, we searched for the metabolism of their active drugs. In addition, we further characterized each compound based on (1) whether phase I and/or II reactions were involved in its metabolism, (2) if it or its active metabolite has 10% biliary excretion, (3) which cytochrome P450 enzyme is predominantly involved in its metabolism, and (4) average daily dose ( 10 mg, mg, or 50 mg) as defined elsewhere. 17 We subsequently searched for reports of selected hepatic adverse events for each of these 207 compounds utilizing Thompson s Micromedex (DRUGDEX) System 13 The DRUGDEX is a comprehensive pharmacy database, consisting of package insert data and published literature. 13 To ensure completeness, each compound was cross-checked in PubMed, the U.S. Food and Drug Administration s Adverse Event Reporting System database, and the Physicians Desk Reference. 18 Hepatic adverse events of interest were alanine aminotransferase (ALT) 3 times the upper limit of normal (ULN), cholestatic jaundice, liver failure, liver transplantation, and fatal DILI. For the purposes of the study, fatal DILI was defined as drug-induced acute liver failure resulting in death. We did not take into account the total number of reported adverse events for a single compound; rather, we identified if a particular event has ever been reported for that compound. This allowed us to compute the proportion of compounds in each metabolism subgroup to cause prespecified hepatic adverse events. This study essentially represents an extension of our earlier published work that investigated the relationship between daily dose of oral medication and reports of hepatic adverse events. 17 The primary data analysis compared the frequency of hepatic adverse events between compounds with and without significant hepatic metabolism. Additional analyses were conducted to examine the relationship between the reports of hepatic adverse events and (1) the type of hepatic metabolism (i.e., phase I and/or II), (2) the biliary excretion of the parent compound or its active metabolite, (3) the predominant CYP involved, and (4) the combination of hepatic metabolism and average daily dose. The results are expressed as the percentages of drugs able to cause an adverse effect rather than the frequencies of these adverse events in treated patients. Descriptive statistics such as the mean plus standard deviation and percentages were used to characterize the cohort. Categorical variables were tested for statistical significant differences by way of the chi-square or Fisher s exact test and continuous variables by way of the Student t test; P 0.05 was considered statistically significant.
3 HEPATOLOGY, Vol. 51, No. 2, 2010 LAMMERT ET AL. 617 Table 1. Relationship Between Extent of Hepatic Metabolism and Reports of Hepatic Adverse Events ALT >3 ULN (n 58) Jaundice (n 86) Liver Failure (n 47) Liver Transplantation (n 14) Fatal DILI (n 36) Compounds with significant hepatic metabolism (n 149) 35% 46% 28% 9% 23% Compounds without significant hepatic metabolism (n 55) 11% 35% 9% 2% 4% P value Percentages are representative of row value. Three compounds with no information on their metabolism were excluded (nitrofurantoin, dicyclomine, docusate). Compounds with significant hepatic metabolism had significantly higher reports of hepatic adverse events, including ALT 3 times the ULN, liver failure, liver transplantation, or fatal DILI versus those without significant hepatic metabolism. For example, 35% of compounds with significant hepatic metabolism have reports of ALT 3 times the ULN compared with 11% of compounds without significant hepatic metabolism (P 0.001). Results Out of 207 eligible compounds, 149 belonged to the significant hepatic metabolism group and 55 to the nonsignificant hepatic metabolism group (Supporting Table 1). There were three compounds for which the details of their metabolism could not be identified (docusate, dicyclomine, nitrofurantoin). The mean number of prescriptions written for the significant hepatic metabolism group was 7,954,705 and was not statistically different from the nonsignificant hepatic metabolism group (9,068,470, P 0.5). Thirty-six percent of the compounds in the significant hepatic metabolism group had an average daily dose of 50 mg versus 51% of the compounds in the nonsignificant hepatic metabolism group (P 0.03). Compared with compounds without significant hepatic metabolism, compounds in the significant hepatic metabolism group were significantly more likely to have reports of ALT 3 times the ULN (35% versus 11%, P 0.001), liver failure (28% versus 9%, P 0.004), and fatal DILI (23% versus 4%, P 0.001), but not liver transplantation (9% versus 2%, P 0.11) or jaundice (46% versus 35%, P 0.2) (Table 1). Compared with compounds metabolized only through phase I reactions, compounds metabolized through both phase I and II reactions did not have greater frequency of jaundice (P 0.74), liver failure (P 0.36), liver transplantation (P 0.36), or fatal DILI (P 0.56), but had significantly higher reports of ALT 3 times the ULN (45% versus 28%, P 0.03) (Table 2). There were nine compounds with metabolism only through phase II reactions; of these, one had ALT 3 times the ULN, four had jaundice, two had liver failure, one caused liver transplantation, and two caused fatal DILI (Table 2). These nine compounds were levothyroxine, telmisartan, metoclopramide, hydralazine, prednisolone, topiramate, labetalol, and niacin. There were 50 compounds with documented biliary excretion of the parent compound or its active metabolite. When compared with those without biliary excretion, compounds with biliary excretion had significantly higher frequency of jaundice (74% versus 40%, P ) but not other hepatic adverse events (Table 3). Table 4 shows the relationship between hepatic adverse events and metabolism through four common CYPs. There are potentially significant differences among different CYP pathways and reports of liver failure and fatal DILI. In general, CYP2C9 and CYP2C19 pathways appeared more toxic than CYP3A and CYP2D6 (Table 4). There were 12 compounds without any hepatic metabolism (Table 5). Interestingly, none of these has been reported to cause liver failure, liver transplantation, or fatal DILI, but five compounds have been reported to cause jaundice (Table 5). Table 6 shows the relationship between hepatic adverse events and combination of hepatic metabolism and average daily dose. It appears that compounds with both significant hepatic metabolism and average daily dose 50 mg (n 50) are significantly more hepatotoxic than compounds belonging to other groups (Table 6). When compared with compounds in all other groups combined, compounds with both significant hepatic metabolism and average daily dose 50 mg had significantly higher fre- Table 2. Relationship Between Type of Hepatic Metabolism and Reports of Hepatic Adverse Events ALT >3 ULN Jaundice Liver Failure Liver Transplantation Fatal DILI Only phase I reactions (n 117) 28% 46% 24% 6% 21% Both phase I and II reactions (n 57) 45% 49% 33% 11% 26% P value Percentages are representative of row value. Compounds with no hepatic metabolism (n 11), only phase II metabolism (n 9), and unknown details of phase I and II reactions (n 13) were not included in this analysis. Of nine compounds with metabolism only through phase II reactions alone (levothyroxine, telmisartan, metoclopramide, hydralazine, prednisolone, topiramate, lamotrigine, labetalol, and niacin), one caused ALT 3 times the ULN, four caused jaundice, two caused liver failure, one caused liver transplantation, and two caused fatal DILI.
4 618 LAMMERT ET AL. HEPATOLOGY, February 2010 Table 3. Relationship Between Biliary Excretion and Reports of Hepatic Adverse Events ALT >3 ULN Jaundice Liver Failure Liver Transplantation Fatal DILI Compounds with biliary excretion (n 50) 36% 74% 28% 10% 24% Compounds without reported biliary excretion (n 157) 26% 40% 24% 6% 18% P value Percentages are representative of row value. Compounds with biliary excretion are significantly more likely to cause jaundice (which in majority is cholestatic) than compounds without biliary excretion (74% versus 40%, respectively; P ). quency of liver failure (P 0.002), liver transplantation (P 0.002), and fatal DILI (P 0.003). When compared with compounds in any other group separately, compounds with both significant hepatic metabolism and average daily dose 50 mg had a higher frequency of ALT 3 times the ULN (P 0.01), liver failure (P 0.001), liver transplantation (P 0.08), and fatal DILI (P 0.006) than other single group (Table 6). Discussion The pathogenesis of idiosyncratic DILI is not well understood. Traditionally, it is thought to be unpredictable and not dose-dependent. However, in a recent study consisting of pharmaceutical databases, we have uncovered epidemiological signals to suggest that there may be a daily dose threshold ( 50 mg) beyond which oral medications have increased risk of serious DILI events. 17 The current study was undertaken to examine the relationship between metabolism characteristics of medications and the risk of hepatic adverse events. Although some drugs are metabolized into stable metabolites, many drugs are transformed into unstable and potentially reactive metabolites that can bind to and attack hepatic macromolecules. 19 Although reactive metabolites are considered to be of major importance in the pathogenesis of DILI, this has not been systematically investigated previously for the overall risk for DILI. If this reactive metabolite theory is shown to be true for the overall risk for DILI, this is obviously of concern in the development of new drugs. We hypothesized that compounds with significant hepatic metabolism may potentially be more hepatotoxic due to the generation of reactive intermediaries and subsequent metabolic idiosyncrasy. Indeed, our epidemiological survey uncovered many associations between metabolic characteristics of medications and the risk of hepatic adverse events. This study is an extension of our previously published study that systematically examined the relationship between daily dose of oral medications and hepatic adverse events. Although the present study stems from the database and consists of the same set of oral compounds as our previous study, it addressed different hypotheses and uncovered key findings that have not been reported previously. First, a significantly higher proportion of compounds with significant hepatic metabolism had reports of ALT 3 times the ULN, liver failure, liver transplantation, and fatal DILI versus compounds with lesser degrees of hepatic metabolism. It is striking that none of the 12 compounds without any hepatic metabolism had any identifiable reports of liver failure, liver transplantation, or fatal DILI. This does not necessarily mean that compounds without hepatic metabolism are entirely immune from hepatotoxicity, but it is significantly less likely. One example of a drug in which selective hepatic metabolism did not cause serious hepatotoxicity is ximelagatran, which was not approved by the Food and Drug Administration due to cases of hepatotoxicity during its development Because this medication was never approved for clinical use in the United States, it was not included in our study. Another example is pregabalin, which is also without hepatic metabolism but may be rarely associated with suspected severe hepatotoxicity. 20 Because it was approved in December 2004, it was not included in our Table 4. Relationship Between Hepatic Adverse Events and Metabolism Through Specific CYP ALT >3 ULN Jaundice Liver Failure Liver Transplantation Fatal DILI CYP 3A (n 75) 33% 40% 16% 5% 13% CYP 2D6 (n 50) 30% 46% 25% 6% 16% CYP 2C19 (n 23) 30% 56% 43% 17% 35% CYP 2C9 (n 34) 35% 53% 38% 6% 32% P value Percentages are representative of row value. If a compound is metabolized by multiple CYPs, it is assigned to the predominant CYP involved in its metabolism. In instances of equal contribution by two different CYPs, a compound is included for both CYPs. These data suggest that there may be a significant difference among different CYP pathways involved and the reports of drug-induced liver failure (P 0.01) and drug-induced death caused by liver injury (P 0.03). In general, CYP2C9 and CYP2C19 enzymes appear more associated with toxicity than CYP3A and CYP2D6.
5 HEPATOLOGY, Vol. 51, No. 2, 2010 LAMMERT ET AL. 619 Table 5. Compounds Without Hepatic Metabolism Categorized into Average Daily Dose (n 12) Daily Dose <10 mg Daily Dose mg Daily Dose >50 mg Risedronate Alendronate Cefdinir Hydrochlorothiazide* Cefprozil * Nadolol Gabapentin * Metformin * Cephalexin Benzonatate Cefuroxime * Sotalol None of these compounds has been reported to cause liver failure, liver transplantation, or fatal DILI. *Compounds that have been reported to cause jaundice. Note that 50% of compounds with a daily dose of 50 mg have been associated with jaundice, but only sotalol has been identified as having any biliary excretion. brand name compound category. Thus, lack of hepatic metabolism does not assure total lack of hepatotoxicity, but based on our data it indeed appears to be quite rare. According to the pharmacological interaction hypothesis, some drugs may be able to initiate an immune response through a reversible interaction with the major histocompatibility complex T cell receptor complex. 21 It has been postulated that ximelagatran leads to hepatotoxicity by evoking an immune response by binding directly but reversibly to major histocompatibility complex. 10 Second, we did not find a significant relationship between the frequency of hepatic adverse events and whether a compound is metabolized by phase I and/or phase II reactions. Compounds with only phase II metabolism were not immune from hepatic adverse events. If confirmed, these observations are important, because they argue against a singular role for reactive metabolites generated by phase I reactions in causing hepatotoxicity. Third, we found a statistically significant relationship between reports of jaundice and whether a compound has biliary excretion. Although it was not always clear from the reports contained within the DRUGDEX whether jaundice is hepatocellular or cholestatic in nature, we found that it was cholestatic in a substantial proportion. This leads us to speculate that compounds with biliary excretion may cause cholestatic jaundice in genetically predisposed individuals (e.g., defective transporters). There is increasing evidence that cholestatic liver injury associated with certain compounds results from a drug- or metabolite-mediated inhibition of hepatobiliary transport systems. 22 Furthermore, we observed an additive effect of daily dose and hepatic metabolism; oral compounds with significant hepatic metabolism but also given at daily doses 50 mg had the highest risk of hepatic adverse drug reactions compared with other groups (Table 6). Our observation of a relationship between daily dose and idiosyncratic DILI has recently been confirmed in more than 600 prospectively collected DILI cases included in the Spanish hepatotoxicity registry. 23 It is striking that 77% of their compounds belonged to the 50 mg/day category, exactly the same proportion that we reported in our earlier study. 17 Our current observations extend our previous findings and may have important implications for future drug development. Based on our data, it is tempting to suggest that the pharmaceutical industry should focus on developing compounds that are administered at doses 50 mg/day and without significant hepatic metabolism. Several aspects of this study deserve further discussion. It shares the same drawbacks as our earlier study that examined the relationship between daily dose and DILI. 17 First, this is largely a systematic survey of the published literature, thus our observations should be viewed as epidemiological clues rather than confirmed facts. Second, it Table 6. Relationship Between Hepatic Metabolism, Daily Dose, and Reports of Hepatic Adverse Events Average Daily Dose Nonsignificant Hepatic Metabolism (n 55) Significant Hepatic Metabolism (n 149) <10 mg (n 9) mg (n 18) >50 mg (n 28) <10 mg (n 40) mg (n 59) >50 mg* (n 50) ALT 3 ULN 22% 22% 18% 20% 25% 46% Jaundice 44% 55% 40% 35% 34% 60% Liver failure 0 11% 14% 20% 14% 50% Liver transplantation 0 0 7% 0 3% 18% Fatal DILI 0 11% 3.5% 15% 12% 40% Percentages are representative of column value. For example, 22% of compounds with nonsignificant hepatic metabolism and average daily dose 10 mg were reported to cause ALT 3 times the ULN. *P values for the significant hepatic metabolism plus 50 mg daily dose group versus all other groups combined (ALT 3 times the ULN 0.057, jaundice 0.06, liver failure 0.002, liver transplantation 0.002; fatal DILI 0.002). P 0.01 versus any other value in the same row. For example, significantly more compounds in the significant hepatic metabolism plus 50 mg daily dose group had reports of ALT 3 ULN versus any other group.
6 620 LAMMERT ET AL. HEPATOLOGY, February 2010 should be noted that the 50% cutoff that defined significant hepatic metabolism was chosen arbitrarily and was based on consensus, thus it may or may not reflect biological significance. Third, although an extensive search of multiple databases was conducted to decipher metabolism characteristics of eligible compounds, some uncertainties remain. For example, there remained three compounds (docusate, nitrofurantoin, and dicyclomine) whose metabolism profile could not be identified. Similarly, topiramate, which we classified as having only phase II metabolism, is primarily eliminated unchanged in the urine ( 70%). Finally, we have not considered alterations in metabolism induced by coadministered medications (e.g., antiepileptic agents or antifungal agents). Despite the above limitations, our observations are potentially important, and we believe they are worthy of further investigation. Because DILI is a rare clinical event, it is difficult to design prospective studies that address questions of this nature. Proprietary datasets owned by the pharmaceutical industry may provide further opportunities for data mining, especially when multiple datasets are investigated in aggregate. If our findings can be reproduced by other investigations, then our observations may facilitate the development of safer medications. References 1. Gibson GG, Skett P. Introduction to Drug Metabolism. 3rd ed. Cheltenham, UK: Nelson Thornes, Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem Res Toxicol 2008;21: Abboud G. Kaplowitz N. Drug-induced liver injury. Drug Saf 2007;30: Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354: Walgreen JL, Mitchell MD, Thompson DC. Role of metabolism in druginduced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005;35: Watkins PB. The role of cytochrome P450s in drug-induced liver disease. In: Kaplowitz N, DeLeve LD, eds. Drug-Induced Liver Disease. 1st ed. New York: Marcel Dekker, Inc.; 2003: Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the danger hypothesis and innate immune system. Chem Res Toxicol 1999;12: Tang W, Stearns RA, Bandeira SM, Zhang Y, Raab C, Braun MP, et al. Studies on cytochrome P-450 mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. Drug Metab Dispos 1999;27: Lewis JH, Larrey D, Olsson R, Lee WM, Frison L, Keisu M. Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran. Int J Clin Pharmacol Ther 2008;46: Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008;8: Drug Topics. Top 200 brand drugs by units in Available at: /article.pdf. Accessed November 2, Drug Topics. Top 200 generic drugs by units in Available at: /article.pdf. Accessed November 2, DRUGDEX system. Available at: drugdex/. Accessed November 2, Dollery C, ed. Therapeutic Drugs. 2nd ed. Edinburgh, UK: Churchill Livingstone; McEnvoy GK. AHFS Drug Information. London: Transatlantic Publishers; FASS the Swedish Medicines Information Engine. Available at Accessed February 1, Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver disease: search for signals. HEPATOLOGY 2008;47: Physician Desk Reference. Available at: aspx. Accessed November 2, Pessayre D. Role of reactive metabolites in drug-induced hepatitis. J Hepatol 1995;23: Einarsdottir S, Björnsson E. Pregabalin as a probable cause of acute liver injury. Eur J Gastroenterol Hepatol 2008;20: Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002;2: Pauli-Magnus C, Meier PJ. Hepatobiliary transporters and drug-induced cholestasis. HEPATOLOGY 2006;44: Lucena MI, Andrade RJ, Kaplowitz N, García-Cortes M, Fernández MC, Romero-Gomez M, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and gender. HEPATOLOGY 2009;49:
DILI: Clinical Pharmacology Considerations for Risk Assessment
DILI: Clinical Pharmacology Considerations for Risk Assessment Raj Madabushi, PhD Office of Clinical Pharmacology Drug-Induced Liver Injury (DILI) Conference XVII June 06, 2017 Disclaimer: The views expressed
More informationHBV Forum 2 April 18 th 2017 Hilton Amsterdam.
HBV Forum 2 April 18 th 2017 Hilton Amsterdam www.forumresearch.org Detection, Assessment and Management of DILI During Drug Development for HBV: The IQ DILI Initiative. Arie Regev, MD Global Patient Safety
More informationDiagnostic evaluation of suspected Drug-Induced Liver Injury
Diagnostic evaluation of suspected Drug-Induced Liver Injury Ynto de Boer, MD Department of Gastroenterology and Hepatology Disclosure No disclosures Drug-induced liver injury? Outline What is DILI? What,
More informationChemically Reactive Drug Metabolites in Drug Discovery and Development Detection, Evaluation, and Risk Assessment
Chemically Reactive Drug Metabolites in Drug Discovery and Development Detection, Evaluation, and Risk Assessment Pacific Northwest Bio Meeting Seattle, WA, August 14, 2012 Thomas A. Baillie, PhD, DSc
More informationB. Incorrect! Compounds are made more polar, to increase their excretion.
Pharmacology - Problem Drill 04: Biotransformation Question No. 1 of 10 Instructions: (1) Read the problem and answer choices carefully, (2) Work the problems on paper as 1. What is biotransformation?
More informationOverview of Causality Assessment in Drug-Induced Liver Injury
REVIEW Overview of Causality Assessment in Drug-Induced Liver Injury Paul H. Hayashi, M.D., M.P.H. The diagnosis of drug-induced (or herbal/dietary supplement induced) liver injury (DILI) remains largely
More informationA comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications
/, Vol.6, No. 19 A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications Zuquan Weng 1,*, Kejian Wang 1,*, Haibo
More informationDrug-Induced Liver Injury
SUPPLEMENT ARTICLE Drug-Induced Liver Injury Neil Kaplowitz Gastroenterology/Liver Division, Keck School of Medicine, University of Southern California, Los Angeles Drug-induced hepatotoxicity is a frequent
More informationHHS Public Access Author manuscript Hepatology. Author manuscript; available in PMC 2017 March 01.
Febuxostat-Induced Acute Liver Injury Matt Bohm, DO, Raj Vuppalanchi, MD, Naga Chalasani, MD, and Drug Induced Liver Injury Network (DILIN) Department of Medicine, Indiana University School of Medicine,
More informationClick to view Biosketch and Presentation Abstract or page down to review presentation
Alexander Gerbes, MD Professor of Internal Medicine, Medizinische Klinik und Poliklinik II Klinikum der Universität München, FRG Andreas Benesic, MD Physician, Researcher Medizinische Klinik und Poliklinik
More informationAbstract AIM: To analyze the clinical features of druginduced liver injury (DILI), and discuss the risk factors affecting its prognosis.
: http://www.baishideng.com/wcjd/ch/index.aspx : http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.11569/wcjd.v24.i8.1257 2016 3 18 ; 24(8): 1257-1263 ISSN 1009-3079 (print) ISSN 2219-2859 (online) 2016
More informationLeonard B. Seeff, M.D. Consultant Einstein Healthcare Network. Click to view Biosketch and Presentation Abstract or page down to review presentation
Leonard B. Seeff, M.D. Consultant Einstein Healthcare Network Click to view Biosketch and Presentation Abstract or page down to review presentation ALT as a Biomarker for Drug-Induced Liver Injury Leonard
More informationDrug-induced liver injury
Drug-induced liver injury Vincent Wong MBChB(Hons), MD, FRCP, FHKCP, FHKAM Professor, Department of Medicine and Therapeutics Director, Cheng Suen Man Shook Foundation Centre for Hepatitis Studies Deputy
More informationChapter 4. Drug Biotransformation
Chapter 4 Drug Biotransformation Drug Biotransformation 1 Why is drug biotransformation necessary 2 The role of biotransformation in drug disposition 3 Where do drug biotransformation occur 4 The enzymes
More informationDrug-induced liver injury due to varenicline: a case report
Sprague and Bambha BMC Gastroenterology 2012, 12:65 CASE REPORT Drug-induced liver injury due to varenicline: a case report David Sprague 1 and Kiran Bambha 2* Open Access Abstract Background: Liver injury
More informationDrug Induced Liver Injury: A Clinical Perspective. Robert J. Fontana, MD
Drug Induced Liver Injury: A Clinical Perspective Robert J. Fontana, MD Drug induced liver injury (DILI) is an uncommon cause of acute and chronic liver injury of increasing importance to patients, clinicians,
More informationHepatotoxicity due to Isoniazide in a Patient with Crohn s Disease: Case Report and Literature Review
Case report Hepatotoxicity due to Isoniazide in a Patient with Crohn s Disease: Case Report and Literature Review Gustavo Adolfo Reyes M., MD, 1 Germán David Carvajal P., MD, 2 Mónica Lorena Tapias M.,
More informationDrug Induced Liver Injury (DILI)
Drug Induced Liver Injury (DILI) Aisling Considine- Consultant Hepatology Pharmacist. King s College Hospital NHS Foundation Trust aislingconsidine@nhs.net Drug Induced Liver Injury /Disease Acute Liver
More informationEvaluation of prognostic markers in severe drug-induced liver disease
PO Box 2345, Beijing 100023, China World J Gastroenterol 2007 January 28; 13(4): 628-632 World Journal of Gastroenterology ISSN 1007-9327 wjg@wjgnet.com 2007 The WJG Press. All rights reserved. RAPID COMMUNICATION
More informationA Severe Hepatotoxicity by Antituberculosis Drug, and its Recovery in Oriental Hospital
J Korean Med. 2016;37(2):119-124 pissn 1010-0695 eissn 2288-3339 Case Report A Severe Hepatotoxicity by Antituberculosis Drug, and its Recovery in Oriental Hospital Chang-Gue Son Liver and Immunology Research
More informationDrug Induced Liver Injury (DILI) Sumita Verma Senior Lecturer Medicine, Hon Consultant Hepatologist Brighton and Sussex Medical School
Drug Induced Liver Injury (DILI) Sumita Verma Senior Lecturer Medicine, Hon Consultant Hepatologist Brighton and Sussex Medical School Disclosures None pertaining to current talk Research grants from Gilead,
More informationIdiosyncratic drug-induced liver injury (DILI) is rare,
Relationship Between Daily Dose of Oral Medications and Idiosyncratic Drug-Induced Liver Injury: Search for Signals Craig Lammert, 1 Stefan Einarsson, 2 Chandan Saha, 3 Anna Niklasson, 2 Einar Bjornsson,
More informationWilliam M. Lee, MD. Aim: Discuss Clinical Trends in DILI and Acetaminophen Liver Injury
Drug-Induced Liver Injury (DILI) including Acetaminophen (APAP) 2014: Practical Tips William M. Lee, MD Clinical Professor Department of Internal Medicine Division of Gastroenterology, Hepatology & Nutrition
More informationAim: Discuss Clinical Trends in DILI and Acetaminophen Liver Injury
Drug-Induced Liver Injury (DILI) including Acetaminophen (APAP) 2014: Practical Tips DILI 2014: Aims/Topics Aim: Discuss Clinical Trends in DILI and Acetaminophen Liver Injury William M. Lee, MD Clinical
More informationMechanism of Action of N-Acetylcysteine in the Protection Against the Hepatotoxicity of Acetaminophen in Rats In Vivo
Mechanism of Action of N-Acetylcysteine in the Protection Against the Hepatotoxicity of Acetaminophen in Rats In Vivo BERNHARD H. LAUTERBURG, GEORGE B. CORCORAN, and JERRY R. MITCHELL, Baylor College of
More informationChronic Liver Disease after Acute Hepatocellular DILI
Chronic Liver Disease after Acute Hepatocellular DILI Robert J. Fontana, MD University of Michigan Medical Center DILI Natural history of acute DILI Transplant/ death Chronic DILI Chronic DILI Incidence
More informationCase Report Diphenhydramine as a Cause of Drug-Induced Liver Injury
Hindawi Case Reports in Hepatology Volume 217, Article ID 3864236, 4 pages https://doi.org/1.1155/217/3864236 Case Report Diphenhydramine as a Cause of Drug-Induced Liver Injury Yunseok Namn, 1 Yecheskel
More informationx B versus x ULN for Assessing Drug Effects
x B versus x ULN for Assessing Drug Effects Leonard B. Seeff, M.D. The Hill Group and the U.S. Food and Drug Administration Detecting and Evaluating Drug-Induced Liver Injury and Dysfunction University
More informationRecent Status of Drug-induced Liver Injury and Its Problems in Japan
Research and Reviews Recent Status of Drug-induced Liver Injury and Its Problems in Japan JMAJ 53(4): 243 247, 2010 Hajime TAKIKAWA* 1 Abstract Adverse drug reactions are becoming a social issue in recent
More informationSuspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane.
ISPUB.COM The Internet Journal of Anesthesiology Volume 25 Number 1 Suspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane. V Sampathi,
More informationHMG Co-A reductase inhibitors, popularly known as CLINICAL LIVER, PANCREAS, AND BILIARY TRACT
GASTROENTEROLOGY 2004;126:1287 1292 CLINICAL LIVER, PANCREAS, AND BILIARY TRACT Patients With Elevated Liver Enzymes Are Not at Higher Risk for Statin Hepatotoxicity NAGA CHALASANI,* HISHAM ALJADHEY, JOE
More informationCYP1A2 polymorphism in Chinese patients with acute liver injury induced by Polygonum multiflorum
CYP1A2 polymorphism in Chinese patients with acute liver injury induced by Polygonum multiflorum K.F. Ma, X.G. Zhang and H.Y. Jia The First Affiliated Hospital, Zhejiang University, Hangzhou, China Corresponding
More informationDrug Induced Liver Injury at a Tertiary Hospital in India: Etiology, Clinical Features and Predictors of Mortality
442 ORIGINAL ARTICLE May-June, Vol. 16 No. 3, 2017: 442-450 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for Study of the Liver and the Canadian Association
More informationThe importance of pharmacogenetics in the treatment of epilepsy
The importance of pharmacogenetics in the treatment of epilepsy Öner Süzer and Esat Eşkazan İstanbul University, Cerrahpaşa Faculty of Medicine, Department of Pharmacology and Clinical Pharmacology Introduction
More informationBSEP inhibition and Drug Induced Liver Injury
BSEP inhibition and Drug Induced Liver Injury Gerry Kenna Pharmaceutical Director, Safer Medicines Trust www.safermedicines.org Drug Safety Consultant Overview Drug Induced Liver Injury (DILI) BSEP inhibition
More informationDrug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment Options
Drug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment Options The Harvard community has made this article openly available. Please share how this access benefits
More informationThe liver in poisoning: what can we learn from animal models?
The liver in poisoning: what can we learn from animal models? Stephan Krähenbühl Clinical Pharmacology & Toxicology University Hospital 4031 Basel/Switzerland Kraehenbuehl@uhbs.ch Outcome and causes of
More informationA Case of Cold Medicine-Induced Hepatitis Treated with Herbal Medicine
2011. Vol.32. No.6. 112-116 The Journal of Korean Oriental Medicine Case Report A Case of Cold Medicine-Induced Hepatitis Treated with Herbal Medicine Chang-Gue Son Liver and Immunology Research Center,
More informationIntrinsic vs. Idiosyncratic DILI
Idiosyncratic Drug Induced Liver Injury Naga Chalasani, MD, FACG Professor & Director Division of GI and Hepatology Indiana University School of Medicine Clarian/IU Digestive Diseases Center ACG PG Course
More informationMoving from Preclinical to Clinical Studies
Global Product Patient Safety Biomarkers for DILI: Moving from Preclinical to Clinical Studies Arie Regev, M.D. Global Patient Safety Eli Lilly and Company Indianapolis, IN New IDILI Biomarkers in the
More informationDrug induced liver injury: accuracy of diagnosis in published reports
248 Teschke R, et al., 2014; 13 (2): 248-255 ORIGINAL ARTICLE March-April, Vol. 13 No. 2, 2014: 248-255 Drug induced liver injury: accuracy of diagnosis in published reports Rolf Teschke,* Christian Frenzel,**
More informationDrug-, herb- and dietary supplement-induced liver injury
Special article Arch Argent Pediatr 2017;115(6):e397-e403 / e397 Drug-, herb- and dietary supplement-induced liver injury María L. Cavalieri, M.D. a and Daniel D Agostino, M.D. a a. Department of Pediatric
More informationToxicology Research REVIEW. Introduction. Rosa Chan and Leslie Z. Benet * View Article Online View Journal
REVIEW View Article Online View Journal Cite this: DOI: 10.1039/c8tx00016f Received 11th January 2018, Accepted 17th April 2018 DOI: 10.1039/c8tx00016f rsc.li/toxicology-research Evaluation of the relevance
More informationReliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN)
Liver International ISSN 1478-3223 DRUG-INDUCED LIVER INJURY Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN)
More informationThe HMG-CoA reductase inhibitors (statins) are. Spectrum of Statin Hepatotoxicity: Experience of the Drug-Induced Liver Injury Network
Spectrum of Statin Hepatotoxicity: Experience of the Drug-Induced Liver Injury Network Mark W. Russo, 1 Jay H. Hoofnagle, 2 Jiezhun Gu, 3 Robert J. Fontana, 4 Huiman Barnhart, 3 David E. Kleiner, 5 Naga
More informationValdoxan (agomelatine) in the treatment of Major Depressive Episodes in Adults. Prescriber Guide Information for Healthcare Professionals
Important information Do not discard! Valdoxan (agomelatine) in the treatment of Major Depressive Episodes in Adults Prescriber Guide Information for Healthcare Professionals Recommendations regarding:
More informationPharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne
Pharmacokinetics for Physicians Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne The Important Therapeutic Questions What drug? What dose? How long? Drug Dosage
More informationCase Report Metronidazole Induced Liver Injury: A Rare Immune Mediated Drug Reaction
Volume 2013, Article ID 568193, 4 pages http://dx.doi.org/10.1155/2013/568193 Case Report Metronidazole Induced Liver Injury: A Rare Immune Mediated Drug Reaction Dayakar Kancherla, 1 Mahesh Gajendran,
More informationDrug- induced Liver Injury. Guruprasad P. Aithal
Drug- induced Liver Injury Guruprasad P. Aithal Characterising DILI Deriving case defini=ons Phenotypes and outcomes Manifesta=ons PaBerns Liver histology Cholestasis Terminology Drug- induced Liver disease:
More informationMETABOLISM. Ali Alhoshani, B.Pharm, Ph.D. Office: 2B 84
METABOLISM Ali Alhoshani, B.Pharm, Ph.D. ahoshani@ksu.edu.sa Office: 2B 84 Metabolism By the end of this lecture, you should: Recognize the importance of biotransformation Know the different sites for
More informationTable 1 Some of the drugs that induce DILI and the mechanisms underlying their toxicity
Table 1 Some of the drugs that induce DILI and the mechanisms underlying their toxicity. 54 78 Drug Use Possible mechanism of liver injury Liver injury type Abacavir Acetaminophe n Aspirin Interferon beta
More informationCytokrom P450 (CYP) Hepatic Drug Metabolism. Medicines in plasma. Plasma concentration of a medicine. Eva Brittebo Dept Pharmaceutical Biosciences
Hepatic Drug Metabolism Eva Brittebo Dept Pharmaceutical Biosciences Background Cytochrome P450 (CYP) Liver metabolism Liver toxicity Inhibition and induction Polymorphism 15-05-13 2 Plasma concentration
More informationHepatotoxicity from Biologics? Ross Pierce, M.D. Division of Hematology, OBRR/CBER/FDA
Hepatotoxicity from Biologics? Ross Pierce, M.D. Division of Hematology, OBRR/CBER/FDA Disclaimer The findings and conclusions in this presentation have not been formally disseminated by the Food and Drug
More informationMechanism of Detoxification
Mechanism of Detoxification Prof.Dr. Hedef Dhafir El-Yassin 1 Objectives: 1. To list the detoxification pathways 2. To describe detoxification pathways and phases in the liver, 2 3 4 o Xenobiotics are
More informationDrug-induced hepatotoxicity is a well-recognized adverse. Incidence of Statin Hepatotoxicity in Patients With Hepatitis C
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:902 907 Incidence of Statin Hepatotoxicity in Patients With Hepatitis C SHIRIN KHORASHADI,* NOELLE K. HASSON,* and RAMSEY C. CHEUNG, *Pharmacy Service, and
More informationPaul B. Watkins 1 James H. Lewis. Jaime D. Blais 5 Dan M. Smotzer. Vicente E. Torres 6 Frank S. Czerwiec
Drug Saf (2015) 38:1103 1113 DOI 10.1007/s40264-015-0327-3 ORIGINAL RESEARCH ARTICLE Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease:
More informationVariation in drug responses & Drug-Drug Interactions
Variation in drug responses & Drug-Drug Interactions 1 Properties of an Ideal Drug Effective Safety Selective Reversible Action Predictable Freedom from drug interactions Low cost Chemically stable Sources
More informationWoman, 35, With Jaundice and Altered Mental Status Lauren Kemph, NP
Woman, 35, With Jaundice and Altered Mental Status Lauren Kemph, NP IN THIS ARTICLE Results of case patient s initial laboratory work-up, page 39 Top 10 prescription medications associated with idiosyncratic
More informationToxicant Disposition and Metabolism. Jan Chambers Center for Environmental Health Sciences College of Veterinary Medicine
Toxicant Disposition and Metabolism Jan Chambers Center for Environmental Health Sciences College of Veterinary Medicine chambers@cvm.msstate.edu Definitions Disposition Absorption passage across membrane.
More informationDILI PATHOLOGY. PHILIP KAYE November 2017 BSG Pathology Winter Meeting
DILI PATHOLOGY PHILIP KAYE November 2017 BSG Pathology Winter Meeting General Mechanisms Role of Liver Biopsy Outline Kleiner Categories Pathology! Differentials Severity Finally Drugs/Toxins may cause
More informationShould There Be a Standard of Care (SOC) for Drug-Induced Liver Injury (DILI)? Leonard B Seeff, MD
Should There Be a Standard of Care (SOC) for Drug-Induced Liver Injury (DILI)? Leonard B Seeff, MD Drug-Induced Liver Injury: Are We Ready to Look? March 23-24,2011 AASLD, FDA/CDER, PhRMA A Common Statement
More informationVIRAL HEPATITIS. Definitions. Acute Liver Disease (Hepatitis A &E, Alcoholic hepatitis, DILI and ALF) Acute Viral Hepatitis Symptoms
Acute Liver Disease (Hepatitis A &E, Alcoholic hepatitis, DILI and ALF) Definitions AST and ALT Markers of hepatocellular injury Ryan M. Ford, MD Assistant Professor of Medicine Director of Viral Hepatitis
More informationInhibition of Human Hepatic Bile Acid Transporters as Contributing Factors to Drug-Induced Liver Injury
Inhibition of Human Hepatic Bile Acid Transporters as Contributing Factors to Drug-Induced Liver Injury Kenneth R. Brouwer, Ph.D., RPh Chief Scientific Officer DDI Meeting June 2017 Seattle, Washington
More informationThe Burden of Drug Induced Liver Injury
The Burden of Drug Induced Liver Injury Victor J. Navarro, MD Chairman, Division of Hepatology Einstein Healthcare Network Professor of Medicine Jefferson Medical College Philadelphia, PA, USA Victor J.
More informationValidation of Multivariate Outlier Detection Analyses Used to Identify Potential Drug-Induced Liver Injury in Clinical Trial Populations
ORIGINAL RESEARCH ARTICLE Drug Saf ; 5 (): 865-875 4-596//-865/$49.95/ Adis ª Springer International Publishing AG. All rights reserved. Validation of Multivariate Outlier Detection Analyses Used to Identify
More informationFlavocoxid is a proprietary blend of purified, plantderived
Annals of Internal Medicine Original Research Acute Liver Injury due to Flavocoxid (Limbrel), a Medical Food for Osteoarthritis A Case Series Naga Chalasani, MD; Raj Vuppalanchi, MD; Victor Navarro, MD;
More informationRole of metabolism in Drug-Induced Liver Injury (DILI) Drug Metab Rev. 2007;39(1):
Role of metabolism in Drug-Induced Liver Injury (DILI) Drug Metab Rev. 2007;39(1):159-234 Drug Metab Rev. 2007;39(1):159-234 Drug Metab Rev. 2007;39(1):159-234 A schematic representation of the most relevant
More informationTHBA Platform - Bile acid imbalance
- Bile acid imbalance Bile acids play an important role in maintaining human health by means of signaling molecules in the regulation of bile formation, liver function and metabolism. The detergent effect
More informationBiopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application
Biopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application Leslie Z. Benet, Ph.D. Professor of Bioengineering and Therapeutic Sciences Schools of Pharmacy and Medicine
More informationDrug therapy in patient with hepatic impairment
Drug therapy in patient with hepatic impairment Arzneimitteltherapie bei Leberinsuffizienz Dominik Wilke 03/04 Mai 2018 43. ADKA-Kongress, Stuttgart Functions of the Liver I Metabolism (Carbohydrates,
More informationAbnormal Liver Chemistries. Lauren Myers, MMsc. PA-C Oregon Health and Science University
Abnormal Liver Chemistries Lauren Myers, MMsc. PA-C Oregon Health and Science University Disclosure 1. The speaker/planner Lauren Myers, MMSc, PA-C have no relevant financial relationships to disclose
More informationRecent Advances in Hepatotoxicity of Non Steroidal Anti-inflammatory Drugs
VIEWPINT March-April, Vol. 17 No. 2, 2018: 187-191 187 The fficial Journal of the Mexican Association of Hepatology, the Latin-American Association for Study of the Liver and the Canadian Association for
More informationLabeled Uses: Treatment of Clostiridum Difficile associated diarrhea (CDAD)
Brand Name: Dificid Generic Name: fidaxomicin Manufacturer 1,2,3,4,5 : Optimer Pharmaceuticals, Inc. Drug Class 1,2,3,4,5 : Macrolide Antibiotic Uses 1,2,3,4,5 : Labeled Uses: Treatment of Clostiridum
More informationDemystifying Pharmacogenetics: its evolution and challenges. June 15, 2016
Demystifying Pharmacogenetics: its evolution and challenges June 15, 2016 Welcome! Dr. Brendan Byrne Chief Innovation Officer, TELUS Health Karen Kesteris Director, Product Management, TELUS Health 2 Today
More informationSummary of the Risk Management Plan
Summary of the Risk Management Plan Summary of Risk Management Plan for Esmya (Ulipristal Acetate) This is a summary of the risk management plan (RMP) for Esmya. The RMP details important risks of Esmya,
More informationExploiting BDDCS and the Role of Transporters
Exploiting BDDCS and the Role of Transporters (Therapeutic benefit of scientific knowledge of biological transporters, understanding the clinical relevant effects of active transport on oral drug absorption)
More informationPRESCRIBING IN LIVER AND RENAL DISEASE
THERAPEUTICS FOR INDEPENDENT PRESCRIBERS PRESCRIBING IN LIVER AND RENAL DISEASE Number 6 in a series of 15 articles on Therapeutics Aims and Objectives To outline the pathophysiological changes that occur
More informationFalk Symposium 156: Genetics in Liver Disease. Pharmacogenetics. Gerd Kullak-Ublick
Falk Symposium 156: Genetics in Liver Disease Pharmacogenetics Gerd Kullak-Ublick Division of Clinical Pharmacology and Toxicology Department of Internal Medicine University Hospital Zurich Freiburg, 8.
More informationOverview of PSC Making the Diagnosis
Overview of PSC Making the Diagnosis Tamar Taddei, MD Assistant Professor of Medicine Yale University School of Medicine Overview Definition Epidemiology Diagnosis Modes of presentation Associated diseases
More informationDrug-induced Biliary Disease
Drug-induced Biliary Disease Drug-induced Biliary Disease Pathophysiology Clinical features Pathological features Maastricht 2018 Rob Goldin r.goldin@imperial.ac.uk Pathophysiology Clinical features Pathological
More informationWhen choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E.
... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs Based on a presentation by Barry E. Gidal, PharmD Presentation Summary A physician s choice of an antiepileptic drug (AED) usually depends
More informationOcaliva (obeticholic acid tablets)
Ocaliva (obeticholic acid tablets) Policy Number: 5.01.619 Last Review: 11/2018 Origination: 11/2016 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationDrug-induced liver injury has increasingly become an. Case Report: Fulminant Hepatic Failure Involving Duloxetine Hydrochloride.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:912 917 Case Report: Fulminant Hepatic Failure Involving Duloxetine Hydrochloride A. JAMES HANJE,* LINDSAY J. PELL, NICHOLAS A. VOTOLATO,, WENDY L. FRANKEL,
More information'The efficacy of extracorporeal liver support with molecular adsorbent recirculating system in severe drug-induced liver injury'.
'The efficacy of extracorporeal liver support with molecular adsorbent recirculating system in severe drug-induced liver injury'. Jaishvi Eapen, New York University Rotimi Ayoola, New York University Ram
More informationBasic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics
Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics Learning Outcomes Define biopharmaceutics Describe 4 processes of pharmacokinetics Describe factors that affect medication absorption Describe
More informationSerum microrna biomarkers for human DILI
CLEARANCE DRUG bioactivation covalent binding Detoxication GLUCURONIDE SULPHATE DRUG + METABOLITE chemical stress mitochondrial dysfunction apoptosis necrosis hepatocyte hypertrophy hepatocyte hyperplasia
More informationImpacts of simultaneous administration of omega-3 fatty acids with amoxicillin/clavulanic acid on albino rats' liver and bile
Research Article Impacts of simultaneous administration of omega-3 fatty acids with amoxicillin/clavulanic acid on albino rats' liver and bile Alaa K. J. Al-Rikabi *1, Nada N Alshawi 2 1 Poisoning consultation
More informationBiopharmaceutics Drug Disposition Classification System (BDDCS) and Its Application in Drug Discovery and Development
Biopharmaceutics Drug Disposition Classification System (BDDCS) and Its Application in Drug Discovery and Development Leslie Z. Benet, Ph.D. Professor of Bioengineering and Therapeutic Sciences University
More informationPositive Rechallenge: What Clinical Trial Data Tell Us Julie Papay, Pharm.D. UCB BioSciences Global Patient Safety
Positive Rechallenge: What Clinical Trial Data Tell Us Julie Papay, Pharm.D. UCB BioSciences Global Patient Safety Drug-Induced Liver Injury (DILI) Conference XVI Wednesday 23 March 2016 The comments provided
More informationLiver Function Tests
Liver Function Tests The liver is of vital importance in intermediary metabolism and in the detoxification and elimination of toxic substances. Damage to the organ may not obviously affects its activity
More informationDrug Induced Liver Disease Role of the Pathologist. Disclosure. DILI can never be excluded. Romil Saxena, MD. Dr. Saxena has nothing to Disclose
Drug Induced Liver Disease Role of the Pathologist Romil Saxena, MD Disclosure Dr. Saxena has nothing to Disclose DILI can never be excluded #1 DILI has no specific pattern of injury it can mimic any and
More informationDRUG INDUCED LIVER INJURY DIPENDRA PARAJULI 02/02/2006. University of Louisville
DRUG INDUCED LIVER INJURY DIPENDRA PARAJULI 02/02/2006 EPIDEMIOLOGY - One of the most common forms of ADR - Responsible for - 3-10 % of all reported ADRs - Approx. 2 to 5 % of patients requiring hospitalization
More informationDrug-Induced Liver Injury and Individual Cell Models
Dealing with DILI in Drug Development Dig Dis 2015;33:486 491 Drug-Induced Liver Injury and Individual Cell Models Andreas Benesic a, b Alexander L. Gerbes a a Liver Center Munich, Department of Medicine
More informationINITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY INDICATION AUBAGIO (teriflunomide) is indicated for the treatment of patients with relapsing forms of multiple
More informationCytochrome P450 Drug Interaction Table Flockhart Table
Cytochrome P450 Drug Interaction Table Flockhart Table The table contains lists of drugs in columns under the designation of specific cytochrome P450 isoforms. CYTOCHROME P450 DRUG INTERACTION TABLE A
More informationPrediction of Drug Induced Liver Disease, Pre and Post Marketing
Prediction of Drug Induced Liver Disease, Pre and Post Marketing Sovani Vishwas ABSTRACT Drug induced liver disease is one of the most important causes of drug withdrawals post marketing. The liver is
More informationCaveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Caveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 How to Safeguard that Metrics Reflect E/T Activity? in healthy
More informationIt the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues.
It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues. Primarily depends on: 1.Regional blood flow. 2.Capillary permeability. 3.Protein
More informationHelping the liver to detoxify mycotoxins
Helping the liver to detoxify mycotoxins Mycotoxin strategies have so far focused on binding compounds or detoxifying the compounds by feed additives. Animals however, can also detoxify mycotoxins themselves
More informationDrug-induced liver injury (DILI) is an important
Hepatic Histological Findings in Suspected Drug-Induced Liver Injury: Systematic Evaluation and Clinical Associations David E. Kleiner, 1 Naga P. Chalasani, 2 William M. Lee, 3 Robert J. Fontana, 4 Herbert
More information